| Specificity |
The product is specific for Durvalumab. |
| Host Species |
Mouse |
| Immunogen |
Durvalumab |
| Conjugate |
Unconjugated |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.01-0.1 µg/ml |
| Competitive ELISA |
5-30 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
Lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG2a,κ |
| Clonality |
Monoclonal |
| Clone ID |
15D6 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
ELISA binding of Anti-Durvalumab Antibody (15D6), mAb, Mouse (GenScript, A02031-40) with Durvalumab. While the antibody does not recognize the human IgG (data not shown).
Coating antigen: Durvalumab, 1 µg/ml.
Anti-Durvalumab Antibody (15D6), mAb, Mouse (GenScript, A02031-40) dilution start from 1,000 ng/ml.
EC₅₀= 7.222 ng/ml.
Anti-Durvalumab Antibody (15D6) (GenScript, A02031-40) blocks Durvalumab binding with PD-L1 protein.
Coating antigen: Durvalumab, 0.5 μg/ml.
PD-L1 final concentration: 30 ng/ml.
Anti-Durvalumab Antibody (15D6) (GenScript, A02031-40) dilutions start from 30 μg/ml.
IC₅₀= 1.37 μg/ml.
| Target Background |
Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1κ monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Anti-Durvalumab Antibody (15D6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Durvalumab. |
| Synonyms |
Mouse monoclonal antibody to Imfinzi |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
